"Pyrrolidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds also known as tetrahydropyridines with general molecular formula (CH2)4NH.
| Descriptor ID |
D011759
|
| MeSH Number(s) |
D03.383.773
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrrolidines".
Below are MeSH descriptors whose meaning is more specific than "Pyrrolidines".
This graph shows the total number of publications written about "Pyrrolidines" by people in this website by year, and whether "Pyrrolidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 1 | 3 |
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 1 | 2 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 2 | 3 |
| 2004 | 2 | 2 | 4 |
| 2005 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 3 | 1 | 4 |
| 2017 | 1 | 0 | 1 |
| 2018 | 4 | 0 | 4 |
| 2020 | 2 | 1 | 3 |
| 2021 | 3 | 1 | 4 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 1 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrrolidines" by people in Profiles.
-
Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer. Breast Cancer Res. 2024 Jun 07; 26(1):95.
-
Industry Payments for Vibegron and Prescribing Patterns Among Urologic Clinicians. JAMA Health Forum. 2023 Dec 01; 4(12):e234020.
-
Effect of drug loading and relative humidity on the mechanical properties and tableting performance of Celecoxib-PVP/VA 64 amorphous solid dispersions. Int J Pharm. 2023 Sep 25; 644:123337.
-
Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells. Elife. 2022 05 16; 11.
-
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. J Immunother Cancer. 2022 03; 10(3).
-
Fluorine-18 Labeling of the MDM2 Inhibitor RG7388 for PET Imaging: Chemistry and Preliminary Evaluation. Mol Pharm. 2021 10 04; 18(10):3871-3881.
-
Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study. ESMO Open. 2021 08; 6(4):100200.
-
Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells. Pharm Res. 2021 Jun; 38(6):1067-1079.
-
Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer. Breast Cancer Res. 2021 05 12; 23(1):54.
-
Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU from SARS-CoV-2. Commun Biol. 2021 02 09; 4(1):193.